October « 2020 « Science and Enterprise

Carb-X Funding Nanoscale Sponge to Treat Sepsis

By Alan, on October 21st, 2020%

A company developing tiny particles made of cellular material to soak-up toxins in the body received a $4 million award to advance its sepsis treatment. . . . → Read More: Carb-X Funding Nanoscale Sponge to Treat Sepsis

Growing your Small Business Slowly is Super Important

By Alan, on October 21st, 2020%

Make sure that you don’t grow too quickly or you may end up stunting your own success. . . . → Read More: Growing your Small Business Slowly is Super Important

Software Designed to Model, Visualize Brain Circuits

By Alan, on October 20th, 2020%

An academic-industry team designed a web-based software tool to ease the computer modeling, simulation, and visualization of the brain’s nerve cell circuits. . . . → Read More: Software Designed to Model, Visualize Brain Circuits

Covid-19 Vaccine Challenge Trial Underway

By Alan, on October 20th, 2020%

Researchers in the U.K. are beginning a human challenge trial that intentionally exposes volunteers to SARS-CoV-2 viruses to test candidate vaccines. . . . → Read More: Covid-19 Vaccine Challenge Trial Underway

Myeloma Drug Shown to Treat Covid-19 Patients

By Alan, on October 19th, 2020%

Results from an early clinical trial show a drug designed to treat multiple myeloma also reduces viral loads and hospital stays of patients with Covid-19 infections. . . . → Read More: Myeloma Drug Shown to Treat Covid-19 Patients

Infographic – Covid-19 Brings Down Carbon Emissions

By Alan, on October 17th, 2020%

The chart shows double-digit percentage reductions in carbon dioxide emissions through 31 August for many countries experiencing high Covid-19 infection rates. . . . → Read More: Infographic – Covid-19 Brings Down Carbon Emissions

ALS Drug Shown to Extend Patient Survival

By Alan, on October 16th, 2020%

Results of a clinical trial show a drug to treat amyotrophic lateral sclerosis, or ALS, extends patients’ survival by several months and slows decline of their functions. . . . → Read More: ALS Drug Shown to Extend Patient Survival

Q3 Venture Funds Inch Up, Early-Stage Deals Drop

By Alan, on October 16th, 2020%

Venture capital funding rose in the third quarter of 2020, driven in large part by investments in already established companies rather than newer enterprises. . . . → Read More: Q3 Venture Funds Inch Up, Early-Stage Deals Drop

Lilly Gains Neuro Disease Biotech in $1.36B Deal

By Alan, on October 15th, 2020%

Drug maker Eli Lilly and Co. is acquiring Disarm Therapeutics, a biotechnology company developing treatments for neurodegenerative disorders. . . . → Read More: Lilly Gains Neuro Disease Biotech in $1.36B Deal

Maintaining Your Health Care in the New Normal

By Alan, on October 15th, 2020%

Science and technology can help families regain care of their general health and medical care in many ways. . . . → Read More: Maintaining Your Health Care in the New Normal

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise